PI Industries released Rs 298.1 crore from working capital

PI Industries released Rs 298.1 crore of cash in H1FY27 after net working-capital days fell by 18 to 121 at September 2026 from 139 at March 2026. PI also reported Rs 3,573.7 crore of surplus cash net of debt, despite spending Rs 567.4 crore on capital expenditure during the first half.

How did PI reduce working-capital days by 18?

PI reduced net working-capital days to 121 at September 2026 from 139 at March 2026, releasing Rs 298.1 crore of cash, according to management. The reduction occurred over the first half of FY27 and was based on changes in trade receivables and payables rather than a reduction in inventory days.

Inventory days outstanding, or DIO, were unchanged at 66 days between Q4FY26 and Q2FY27. Trade receivables days sales outstanding, or DSO, decreased by nine days to 117 from 126, while trade payables days payable outstanding, or DPO, increased by nine days to 62 from 53. The lower receivables cycle and longer payables cycle reduced the net working-capital cycle by 18 days.

The reported working-capital balance was Rs 2,264.7 crore at September 2026, compared with Rs 2,562.8 crore at March 2026. This Rs 298.1 crore reduction equals the cash release disclosed by management, while consolidated H1FY27 revenue declined 10% year on year to Rs 3,404.1 crore.

What was PI's cash position at September 2026?

PI reported Rs 3,573.7 crore of surplus cash net of debt at September 2026. Cash, bank balances and investments stood at Rs 3,747.8 crore at that date, compared with Rs 3,509.4 crore at March 2026 and Rs 3,911.4 crore at September 2025.

Cash, bank balances and investments increased by Rs 238.4 crore during the six months to September 2026, but remained Rs 163.6 crore below the September 2025 balance. Short-term debt declined to Rs 69.6 crore at September 2026 from Rs 89.3 crore at March 2026, although it was above Rs 35.5 crore a year earlier.

PI’s debt-to-equity ratio was 0.02 at September 2025, March 2026 and September 2026. Shareholders’ funds rose by Rs 226.9 crore over the six months to Rs 11,457.4 crore, while non-current liabilities were Rs 435.3 crore at September 2026, marginally lower than Rs 436.5 crore in March 2026.

How did PI continue capex during lower earnings?

PI spent Rs 567.4 crore on total capital expenditure in H1FY27 while reporting Rs 3,573.7 crore of surplus cash net of debt at September 2026. Management said the spending supported efficiencies, capacities, new initiatives and research and development, or R&D.

The investment coincided with lower reported earnings in the first half. Consolidated revenue fell to Rs 3,404.1 crore in H1FY27 from Rs 3,772.8 crore in H1FY26, while earnings before interest, tax, depreciation and amortisation, or EBITDA, declined to Rs 605.5 crore from Rs 1,065.3 crore. Net profit fell to Rs 366.4 crore from Rs 809.3 crore.

The working-capital cash release of Rs 298.1 crore was equal to about 53% of the Rs 567.4 crore H1FY27 capex, based on the reported figures. The presentation does not state that this cash was specifically earmarked for capex. Fixed assets including goodwill increased by Rs 364.9 crore during the six months, reaching Rs 6,014.5 crore at September 2026 from Rs 5,649.6 crore at March 2026.

What operating trends accompanied PI's liquidity improvement?

PI’s working-capital improvement occurred while export revenue declined and domestic revenue increased in H1FY27. Exports fell 15.0% to Rs 2,581.9 crore from Rs 3,035.9 crore in H1FY26, whereas domestic revenue rose 11.6% to Rs 822.2 crore from Rs 736.9 crore.

Management attributed the export decline to soft demand and pricing pressure from genericisation in the global agrochemical industry, while disclosing that three molecules were commercialised in H1FY27. Gross margin declined to 53% from 57%, and EBITDA margin fell to 18% from 28% over the same period.

Domestic Biologicals revenue grew more than 55% in H1FY27 and global Biologicals grew more than 96%, according to management. Health Sciences revenue declined 4% in the half year, while management said it would continue expanding the portfolio through new commercialisation. Separately, annualised net sales to net fixed assets decreased to 1.26 at September 2026 from 1.33 at March 2026 and 1.69 at September 2025.

Conclusion

PI combined a reduction in net working-capital days with continued spending on assets during a period of lower H1FY27 revenue and profit. Receivables days fell by nine and payables days rose by nine, while inventory days remained at 66, helping produce the Rs 298.1 crore cash release and leaving Rs 3,573.7 crore of reported surplus cash net of debt at September 2026.

The next disclosures should show whether PI sustains 121 net working-capital days while export demand and genericisation-related pricing pressure remain unresolved. Management also disclosed plans for three peptides registered in US states for a 2027 launch and five Biologicals brands, alongside product-development activity across Brazil, Mexico, Europe and the US.